All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

PHARMACOMPASS

Grow Your Pharma Business Digitally

Find Clinical Drug Pipeline Developments & Deals for 18-Methoxycoronaridine

All Data

Filters

×

FILTER DATA :

Therapeutic Area

Study Phase

Country

News Type

Company

Companies By Therapeutic Area

Development Status

Mind Medicine

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

MindMed Initiates Dosing in Human Safety Study of Novel Treatment for Opioid Addiction, 18-MC

Lead Product(s): 18-Methoxycoronaridine

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 16, 2020

Details:

Data from the current human study is expected to help advance the planning and design of MindMed's future trials of 18-MC in opioid use disorder patients.